explore -WSS

explore

author：entertainment 2025-10-01 00:46:56 - browse：1896

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Medicare drug price negotiation hasn't dried up venture capital

WSS

New Alzheimer's drugs heat up race for early detection blood tests

Carvykti CAR

New lawsuit accuses health insurer Cigna of denying claims in bulk

Medicare drug price negotiation hasn't dried up venture capital

What STAT readers think about the FDA and patient advocacy

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

hotspot

explore

entertainment

Sports medicine is finally prioritizing gender equality

Carvykti CAR

Sports medicine is finally prioritizing gender equality

SEC charges former device maker CEO with $41 million fraud

State Dept. review finds Biden bears some blame for Afghanistan failures

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Trump demands the U.S. pay no more for drugs than other countries … again

UHS says company favors patients whose insurance pays more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Hospitals owned by private equity see complications spike 25%

hotspot

Search called off for baby washed away in Pennsylvania flash flood

A new crop of companies is reshaping the health data economy

Medicare drug price negotiation hasn't dried up venture capital

Virtual care provider acquires bankrupt Pear's prescription apps

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Virtual care provider acquires bankrupt Pear's prescription apps

leisure time

hotspot

entertainment

Wikipedia